You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR LAPATINIB DITOSYLATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Lapatinib Ditosylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00085020 ↗ GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu Completed GlaxoSmithKline Phase 1 2004-03-01 RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Giving GW572016 with trastuzumab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of GW572016 when given together with trastuzumab in treating patients with metastatic breast cancer that overexpresses HER2/neu.
NCT00085020 ↗ GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu Completed National Cancer Institute (NCI) Phase 1 2004-03-01 RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Giving GW572016 with trastuzumab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of GW572016 when given together with trastuzumab in treating patients with metastatic breast cancer that overexpresses HER2/neu.
NCT00085020 ↗ GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu Completed Jonsson Comprehensive Cancer Center Phase 1 2004-03-01 RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Giving GW572016 with trastuzumab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of GW572016 when given together with trastuzumab in treating patients with metastatic breast cancer that overexpresses HER2/neu.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lapatinib Ditosylate

Condition Name

Condition Name for Lapatinib Ditosylate
Intervention Trials
Breast Cancer 21
Stage IV Breast Cancer 11
Stage IIIC Breast Cancer 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lapatinib Ditosylate
Intervention Trials
Breast Neoplasms 38
Carcinoma 14
Breast Neoplasms, Male 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lapatinib Ditosylate

Trials by Country

Trials by Country for Lapatinib Ditosylate
Location Trials
United States 279
Canada 17
Germany 13
Italy 8
Korea, Republic of 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lapatinib Ditosylate
Location Trials
California 19
Pennsylvania 11
New York 11
Ohio 11
Florida 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lapatinib Ditosylate

Clinical Trial Phase

Clinical Trial Phase for Lapatinib Ditosylate
Clinical Trial Phase Trials
Phase 3 5
Phase 2/Phase 3 1
Phase 2 32
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lapatinib Ditosylate
Clinical Trial Phase Trials
Completed 46
Terminated 9
Active, not recruiting 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lapatinib Ditosylate

Sponsor Name

Sponsor Name for Lapatinib Ditosylate
Sponsor Trials
National Cancer Institute (NCI) 48
GlaxoSmithKline 10
European Organisation for Research and Treatment of Cancer - EORTC 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lapatinib Ditosylate
Sponsor Trials
Other 57
NIH 48
Industry 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.